我們已在上線！進一步了解

Zymeworks

ZYME

市值 US$18億

25.03 USD

-0.72

2.8%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

25.03

0.00

0%

1天

-2.8%

5天

-2.07%

1個月

-4.61%

3個月

3.47%

6個月

-7.98%

今年迄今

-5.97%

1年

34.93%

5年

4.25%

10年

92.54%

關於： Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

員工： 264

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 36.4%

中性 63.6%

負面 0%

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business.

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Zymeworks Completes Acquisition of Theravance Biopharma

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks' strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows.

Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

Zacks Investment Research

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Zacks Investment Research

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Zacks Investment Research

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.03 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

查看新聞排名

價格圖表採用Lightweight Charts™實作